GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Apollon Formularies PLC (AQSE:APOL) » Definitions » Retained Earnings

Apollon Formularies (AQSE:APOL) Retained Earnings : £-5.61 Mil (As of Jun. 2023)


View and export this data going back to . Start your Free Trial

What is Apollon Formularies Retained Earnings?

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Apollon Formularies's retained earnings for the quarter that ended in Jun. 2023 was £-5.61 Mil.

Apollon Formularies's quarterly retained earnings declined from Dec. 2021 (£-4.14 Mil) to Jun. 2022 (£-4.36 Mil) and declined from Jun. 2022 (£-4.36 Mil) to Jun. 2023 (£-5.61 Mil).

Apollon Formularies's annual retained earnings increased from Dec. 2019 (£-11.08 Mil) to Dec. 2020 (£-1.61 Mil) but then declined from Dec. 2020 (£-1.61 Mil) to Dec. 2021 (£-4.14 Mil).


Apollon Formularies Retained Earnings Historical Data

The historical data trend for Apollon Formularies's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Apollon Formularies Retained Earnings Chart

Apollon Formularies Annual Data
Trend Jun10 Jun11 Dec12 Dec13 Dec14 Dec17 Dec18 Dec19 Dec20 Dec21
Retained Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only -8.43 -8.75 -11.08 -1.61 -4.14

Apollon Formularies Semi-Annual Data
Jun11 Jun12 Jun13 Dec13 Jun14 Dec14 Jun15 Dec17 Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Jun23
Retained Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.61 -3.31 -4.14 -4.36 -5.61

Apollon Formularies Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.


Apollon Formularies  (AQSE:APOL) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.


Apollon Formularies (AQSE:APOL) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
6 Hope Street, Quayside House, Castletown, IMN, IM9 1AS
Apollon Formularies PLC is a London, England and Jamaican based medical cannabis pharmaceutical company specialising in research and treatment of patients with cancer and chronic pain. It is engaged in investing by seeking to acquire a direct and/or indirect interest in projects and assets in the agriculture and logistics sectors and the medicinal cannabis sector. The company focus on opportunities in Africa and Europe. It has created proprietary hybrid medical cannabis pharmaceutical strains, technology, formulations, and treatment products.

Apollon Formularies (AQSE:APOL) Headlines

From GuruFocus

6 Highly Predictable Companies with Historically Low P/S Ratios

By Dianne Tordillo Dianne Tordillo 11-27-2012

FPA Capital Fund Comments on For-Profit Education Stocks

By Holly LaFon Holly LaFon 12-09-2015

Jeff Auxier Interview with GuruFocus

By Holly LaFon Holly LaFon 08-28-2012

FPA Capital Comments on Apollo Education

By Holly LaFon Holly LaFon 01-30-2017

FPA Capital Fund Q1 2013 Commentary

By Holly LaFon Holly LaFon 04-24-2013

Apollo Education Group Is a Value Trap

By OPM Insights Nelson Hsu 10-15-2015

FPA Capital Fund 4th Quarter 2015 Commentary

By Holly LaFon Holly LaFon 02-08-2016

FPA Capital Fund Comments on Apollo Education Group

By Holly LaFon Holly LaFon 02-09-2016

5 Stocks Trading Near Their Historical Low P/S Ratios

By Holly LaFon Holly LaFon 04-11-2012

FPA Capital Fund Comments on Apollo Education Group Inc

By Vera Yuan Vera Yuan 02-19-2015